STAT3 silencing inhibited HBV replication, which decreased HBV-dependent activation of STAT3 through a negative feedback loop, and augmented the anti-HCC effects (Yang et al., 2016). This evidence concerns the gene STAT3 and hepatocellular carcinoma.